Tag - COGT

Cogent Biosciences Logo

Ladenburg starts Cogent Biosciences at buy; PT $4

Ladenburg Thalmann launched coverage of Cogent Biosciences (NASDAQ:COGT) with a “buy” rating and $4 price target. The stock closed at $2.89 on Oct. 13. Cogent has a late-stage clinical asset, CGT9486, in development for...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.